Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695315 · ClinicalTrials.gov registry record
Tissue-specific Insulin Resistance in Obstructive Sleep Apnea: Role of Hypoxia
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 48
- Enrollment target
NCT03695315: Completed study, sponsored by University of California, San Francisco.
NCT03695315 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03695315 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
Study Summary
Obstructive sleep apnea (OSA) is a common condition associated with significant adverse health outcomes. Our overarching hypothesis is that patients with OSA and hypoxia (H-OSA) have greater degrees of insulin resistance in both liver and adipose tissue when compared to those without hypoxia (NH-OSA) thus leading to increased risk for the development of diabetes in the former group.
Primary Outcome
The percent of newly synthesized fatty acids (DNL, %) will be measured using a stable isotope (deuterated water) and mass spectrometry.
Interventions
- DEVICE Continuous Positive Airway Pressure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2024-12-31 |
What the finished NCT03695315 record still lists
NCT03695315 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 48 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Continuous Positive Airway Pressure is the first listed.
NCT03695315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03695315 about?
NCT03695315 is a clinical study titled "Tissue-specific Insulin Resistance in Obstructive Sleep Apnea: Role of Hypoxia". Obstructive sleep apnea (OSA) is a common condition associated with significant adverse health outcomes. Our overarching hypothesis is that patients with OSA and hypoxia (H-OSA) have greater degrees of insulin resistance in both liver and adipose tissue when compared to those without hypoxia (NH-OSA...
What is the current status of trial NCT03695315?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2018-10-31. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT03695315?
The interventions under investigation include: Continuous Positive Airway Pressure (DEVICE).
Who is sponsoring clinical trial NCT03695315?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI